醛酮还原酶家族1成员B10在胃癌组织中的表达及其临床意义

[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].

作者信息

Yao Hai-bo, Xu Yuan, Chen Le-gao, Guan Tian-pei, Ma Ying-Yu, Tao Hou-quan, Shao Qin-shu

机构信息

Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Feb;16(2):183-7.

PMID:23446484

Abstract

OBJECTIVE

To investigate the association of AKR1B10 expression in gastric cancer tissues with clinicopathologic features and prognosis of gastric cancer patients.

METHODS

Real-time polymerase chain reaction (RT-PCR) was conducted to detect AKR1B10 mRNA expression in gastric cancer and adjacent gastric mucosa tissues (n=36). AKR1B10 protein expression was measured by immunohistochemistry in primary gastric cancer tissues (n=100) and non-tumorous gastric mucosa tissues (n=70).

RESULTS

RT-PCR results confirmed that AKR1B10 was significantly down-regulated in gastric cancer tissues compared with that in paired adjacent mucosa [8.3% (3/36) vs. 91.7% (33/36), P=0.000]. Immunohistochemistry revealed that the percentage of AKR1B10 positive specimens in gastric carcinoma was lower than that in normal specimens [33.0% (33/100) vs. 92.9% (65/70), P=0.000]. The frequencies of positive AKR1B10 in patients was significantly correlated with tumor size (P=0.000), invasive depth (P=0.004), lymph node metastasis (P=0.028), distant metastasis (P=0.031) and TNM stages (P=0.000). The 5-year survival rate of positive AKR1B10 group was significantly higher as compared to negative group (60.6% vs. 32.8%, P<0.01).

CONCLUSION

The down-regulation of AKR1B10 expression in gastric cancer may be associated with the progress of gastric cancer is suggestive of poor prognosis.

摘要

目的

探讨胃癌组织中AKR1B10表达与胃癌患者临床病理特征及预后的关系。

方法

采用实时聚合酶链反应（RT-PCR）检测36例胃癌及癌旁胃黏膜组织中AKR1B10 mRNA的表达。采用免疫组织化学法检测100例原发性胃癌组织及70例非肿瘤性胃黏膜组织中AKR1B10蛋白的表达。

结果

RT-PCR结果证实，与配对的癌旁黏膜相比，胃癌组织中AKR1B10明显下调[8.3%（3/36）对91.7%（33/36），P=0.000]。免疫组织化学显示，胃癌中AKR1B10阳性标本的百分比低于正常标本[33.0%（33/100）对92.9%（65/70），P=0.000]。患者AKR1B10阳性频率与肿瘤大小（P=0.000）、浸润深度（P=0.004）、淋巴结转移（P=0.028）、远处转移（P=0.031）及TNM分期（P=0.000）显著相关。AKR1B10阳性组的5年生存率明显高于阴性组（分别为60.6%和32.8%，P<0.01）。